公开(公告)号：US20240141305A1

公开(公告)日：2024-05-02

申请号：US18488316

申请日：2023-10-17

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Noura S. Abul-Husn ,  Omri Gottesman ,  Alexander Li ,  Xiping Cheng ,  Yurong Xin ,  Jesper Gromada ,  Frederick E. Dewey ,  Aris Baras ,  Alan Shuldiner

IPC分类号： C12N9/04 ,  A61K31/713 ,  A61K38/44 ,  A61K38/46 ,  A61K47/61 ,  A61P1/16 ,  C12N9/22 ,  C12N9/96 ,  C12N15/11 ,  C12N15/113 ,  C12N15/85 ,  C12N15/90 ,  C12Q1/32 ,  C12Q1/6827 ,  C12Q1/6876 ,  C12Q1/6883 ,  G01N33/50

CPC分类号： C12N9/0006 ,  A61K31/713 ,  A61K38/443 ,  A61K38/465 ,  A61K47/61 ,  A61P1/16 ,  C12N9/22 ,  C12N9/96 ,  C12N15/11 ,  C12N15/113 ,  C12N15/1137 ,  C12N15/85 ,  C12N15/907 ,  C12Q1/32 ,  C12Q1/6827 ,  C12Q1/6876 ,  C12Q1/6883 ,  C12Y101/01051 ,  C12Y101/01062 ,  G01N33/5067 ,  A61K48/0066 ,  C12N2310/14 ,  C12N2310/20 ,  C12N2310/531 ,  C12N2320/34 ,  C12Q2600/156

摘要： Provided are compositions related to HSD17B13 variants, including nucleic acid molecules and polypeptides related to variants of HSD17B13, and cells comprising those nucleic acid molecules and polypeptides. Also provided are methods related to HSD17B13 variants. Such methods include methods for detecting the presence of the HSD17B13 rs72613567 variant in a biological sample comprising genomic DNA, for detecting the presence or levels of any one of variant HSD17B13 Transcripts C, D, E, F, G, and H, and particularly D, in a biological sample comprising mRNA or cDNA, or for detecting the presence or levels of any one of variant HSD17B13 protein Isoforms C, D, E, F, G, or H, and particularly D, in a biological sample comprising protein. Also provided are methods for determining a subject's susceptibility to developing a liver disease or of diagnosing a subject with liver disease.

公开(公告)号：US20180216084A1

公开(公告)日：2018-08-02

申请号：US15875192

申请日：2018-01-19

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Noura S. Abul-Husn ,  Omri Gottesman ,  Alexander Li ,  Xiping Cheng ,  Yurong Xin ,  Jesper Gromada ,  Frederick E. Dewey ,  Aris Baras ,  Alan Shuldiner

IPC分类号： C12N9/04 ,  C12Q1/6876 ,  C12Q1/6827 ,  C12Q1/32

CPC分类号： C12N9/0006 ,  A61K38/443 ,  A61K38/465 ,  A61K47/61 ,  A61K48/00 ,  A61P1/16 ,  C12N9/22 ,  C12N9/96 ,  C12N15/11 ,  C12N15/1137 ,  C12N15/85 ,  C12N15/907 ,  C12N2310/14 ,  C12N2310/20 ,  C12N2310/531 ,  C12N2320/34 ,  C12N2800/24 ,  C12N2800/80 ,  C12Q1/32 ,  C12Q1/6827 ,  C12Q1/6876 ,  C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Y101/01051 ,  C12Y101/01062

摘要： Provided are compositions related to HSD17B13 variants, including nucleic acid molecules and polypeptides related to variants of HSD17B13, and cells comprising those nucleic acid molecules and polypeptides. Also provided are methods related to HSD17B3 variants. Such methods include methods for detecting the presence of the HSD17B13 rs72613567 variant in a biological sample comprising genomic DNA, for detecting the presence or levels of any one of variant HSD17B13 Transcripts C, D, E, F, G, and H, and particularly D, in a biological sample comprising mRNA or cDNA, or for detecting the presence or levels of any one of variant HSD17B13 protein Isoforms C, D, E, F, G, or H, and particularly D, in a biological sample comprising protein. Also provided are methods for determining a subject's susceptibility to developing a liver disease or of diagnosing a subject with liver disease.

公开(公告)号：US20100111922A1

公开(公告)日：2010-05-06

申请号：US12607255

申请日：2009-10-28

申请人： Guela Gibori ,  Aurora Shehu

发明人： Guela Gibori ,  Aurora Shehu

IPC分类号： A61K38/44 ,  A01K67/027 ,  C12N5/10 ,  C12Q1/68 ,  A61K31/7088 ,  C07H21/04 ,  A61P25/00 ,  G01N33/48 ,  C12N9/02

CPC分类号： A61K31/7088 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0356 ,  A61K38/443 ,  C07K14/47 ,  C12N9/0006 ,  C12N15/8509 ,  C12Y101/01062

摘要： The present invention features a non-human animal in which is deficient in the expression of endogenous 17β Hydroxysteroid Dehydrogenases Type 7 and use of the same in screening methods for agents that prevent or treat anencephaly. The present invention also provides a method for diagnosing and treating.

摘要翻译： 本发明特征在于一种非人动物，其内源性17和bgr的表达不足; 类固醇类脱氢酶7型及其在预防或治疗脑病的药物筛选方法中的应用。 本发明还提供了一种诊断和治疗方法。

公开(公告)号：US20240352464A1

公开(公告)日：2024-10-24

申请号：US18599052

申请日：2024-03-07

申请人： Aligos Therapeutics, Inc. ,  Merck Sharp & Dohme LLC

发明人： Leonid Beigelman ,  Vivek Kumar Rajwanshi ,  Xuan Luong ,  Kellan Passow ,  Aneerban Bhattacharya ,  Saul Martinez Montero ,  Jerome Deval

IPC分类号： C12N15/113

CPC分类号： C12N15/1137 ,  C12Y101/01062 ,  C12N2310/14

摘要： Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2′-O-methyl nucleotides and 2′-fluoro nucleotides. Further disclosed herein are siNA molecules comprising additional modification including a phosphorylation blocker, conjugated moiety, or 5′-stabilized end cap. The siNA molecules may reduce or inhibit the production of hydroxysteroid dehydrogenase.

公开(公告)号：US20110207172A1

公开(公告)日：2011-08-25

申请号：US13119915

申请日：2010-06-15

申请人： Stefano Fogal ,  Elisabetta Bergantino ,  Riccardo Motterle ,  Andrea Castellin ,  Giancarlo Arvotti

发明人： Stefano Fogal ,  Elisabetta Bergantino ,  Riccardo Motterle ,  Andrea Castellin ,  Giancarlo Arvotti

IPC分类号： C12P33/16 ,  C12N9/04

CPC分类号： C12P33/00 ,  C12N9/0006 ,  C12Y101/01062

摘要： The present invention relates to an industrial process for the reduction of 4-androstene-3,17-dione in order to obtain testosterone using a particularly stable and selective enzyme produced in a recombinant manner.

摘要翻译： 本发明涉及一种用于还原4-雄甾烯-3,17-二酮的工业方法，以便使用以重组方式产生的特别稳定和选择性的酶获得睾酮。

公开(公告)号：US11845963B2

公开(公告)日：2023-12-19

申请号：US15875192

申请日：2018-01-19

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Noura S. Abul-Husn ,  Omri Gottesman ,  Alexander Li ,  Xiping Cheng ,  Yurong Xin ,  Jesper Gromada ,  Frederick E. Dewey ,  Aris Baras ,  Alan Shuldiner

IPC分类号： C12Q1/68 ,  C12P19/34 ,  C12N9/04 ,  C12N15/113 ,  C12Q1/6883 ,  A61K31/713 ,  G01N33/50 ,  C12Q1/32 ,  C12Q1/6827 ,  C12Q1/6876 ,  A61K47/61 ,  A61P1/16 ,  A61K38/44 ,  A61K38/46 ,  C12N9/22 ,  C12N9/96 ,  C12N15/11 ,  C12N15/85 ,  C12N15/90 ,  A61K48/00

CPC分类号： C12N9/0006 ,  A61K31/713 ,  A61K38/443 ,  A61K38/465 ,  A61K47/61 ,  A61P1/16 ,  C12N9/22 ,  C12N9/96 ,  C12N15/11 ,  C12N15/113 ,  C12N15/1137 ,  C12N15/85 ,  C12N15/907 ,  C12Q1/32 ,  C12Q1/6827 ,  C12Q1/6876 ,  C12Q1/6883 ,  C12Y101/01051 ,  C12Y101/01062 ,  G01N33/5067 ,  A61K48/00 ,  A61K48/0066 ,  C12N2310/14 ,  C12N2310/20 ,  C12N2310/531 ,  C12N2320/30 ,  C12N2320/34 ,  C12N2800/24 ,  C12N2800/80 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2333/4704 ,  G01N2800/085

摘要： Provided are compositions related to HSD17B13 variants, including nucleic acid molecules and polypeptides related to variants of HSD17B13, and cells comprising those nucleic acid molecules and polypeptides. Also provided are methods related to HSD17B3 variants. Such methods include methods for detecting the presence of the HSD17B13 rs72613567 variant in a biological sample comprising genomic DNA, for detecting the presence or levels of any one of variant HSD17B13 Transcripts C, D, E, F, G, and H, and particularly D, in a biological sample comprising mRNA or cDNA, or for detecting the presence or levels of any one of variant HSD17B13 protein Isoforms C, D, E, F, G, or H, and particularly D, in a biological sample comprising protein. Also provided are methods for determining a subject's susceptibility to developing a liver disease or of diagnosing a subject with liver disease.

公开(公告)号：US08592178B2

公开(公告)日：2013-11-26

申请号：US13119915

申请日：2010-06-15

申请人： Stefano Fogal ,  Elisabetta Bergantino ,  Riccardo Motterle ,  Andrea Castellin ,  Giancarlo Arvotti

发明人： Stefano Fogal ,  Elisabetta Bergantino ,  Riccardo Motterle ,  Andrea Castellin ,  Giancarlo Arvotti

IPC分类号： C12P33/16 ,  C12N9/00 ,  C12N9/04 ,  C12N1/20 ,  C12N15/00 ,  C07H21/04

CPC分类号： C12P33/00 ,  C12N9/0006 ,  C12Y101/01062

摘要： The present invention relates to an industrial process for the reduction of 4-androstene-3,17-dione in order to obtain testosterone using a particularly stable and selective enzyme produced in a recombinant manner.

摘要翻译： 本发明涉及一种用于还原4-雄甾烯-3,17-二酮的工业方法，以便使用以重组方式产生的特别稳定和选择性的酶获得睾酮。

公开(公告)号：US06994974B1

公开(公告)日：2006-02-07

申请号：US09394204

申请日：1999-09-10

申请人： David M. Stern ,  Shi Du Yan

发明人： David M. Stern ,  Shi Du Yan

IPC分类号： G01N33/53

CPC分类号： C12N9/0006 ,  A01K2217/05 ,  A61K38/00 ,  C07K16/40 ,  C07K2317/54 ,  C07K2319/00 ,  C12Y101/01036 ,  C12Y101/01053 ,  C12Y101/01062 ,  G01N33/6896

摘要： The present invention provides an isolated nucleic acid encoding an endoplasmic reticulum associated amyloid-beta peptide binding (ERAB) polypeptide. The ERAB polypeptide may comprise human ERAB polypeptide. The present invention provides a purified ERAB polypeptide, as well as a method for treating a neurodegenerative condition in a subject which comprises administering to the subject an agent in amount effective to inhibit ERAB polypeptide binding to amyloid-beta peptide so as to thereby treat the neurodegenerative condition.

摘要翻译： 本发明提供编码与内质网相关的淀粉样蛋白-β肽结合（ERAB）多肽的分离的核酸。 ERAB多肽可以包含人ERAB多肽。 本发明提供纯化的ERAB多肽，以及治疗受试者神经变性病症的方法，其包括以有效抑制ERAB多肽与淀粉样蛋白-β肽结合的量向受试者施用试剂，从而治疗神经变性 条件。

公开(公告)号：US20240002857A1

公开(公告)日：2024-01-04

申请号：US18314103

申请日：2023-05-08

申请人： Sanegene Bio USA Inc.

发明人： Chunyang ZHANG ,  Zhongfa YANG ,  Shiyu WANG ,  Weimin WANG ,  Chunxue ZHOU ,  Xiaochuan CAI

IPC分类号： C12N15/113

CPC分类号： C12N15/1137 ,  C12Y101/01062 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/315

摘要： The disclosure relates to isolated oligonucleotides comprising duplex regions targeting hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13), and delivery systems, kits and compositions comprising same, and methods of using same for inhibiting or downregulating HSD17B13.

公开(公告)号：US11753628B2

公开(公告)日：2023-09-12

申请号：US17709965

申请日：2022-03-31

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Noura S. Abul-Husn ,  Omri Gottesman ,  Alexander Li ,  Xiping Cheng ,  Yurong Xin ,  Jesper Gromada ,  Frederick E. Dewey ,  Aris Baras ,  Alan Shuldiner

IPC分类号： C07H21/02 ,  C07H21/04 ,  C12N9/04 ,  C12N15/113 ,  C12Q1/6883 ,  A61K31/713 ,  G01N33/50 ,  C12Q1/32 ,  C12Q1/6827 ,  C12Q1/6876 ,  A61K47/61 ,  A61P1/16 ,  A61K38/44 ,  A61K38/46 ,  C12N9/22 ,  C12N9/96 ,  C12N15/11 ,  C12N15/85 ,  C12N15/90 ,  A61K48/00

CPC分类号： C12N9/0006 ,  A61K31/713 ,  A61K38/443 ,  A61K38/465 ,  A61K47/61 ,  A61P1/16 ,  C12N9/22 ,  C12N9/96 ,  C12N15/11 ,  C12N15/113 ,  C12N15/1137 ,  C12N15/85 ,  C12N15/907 ,  C12Q1/32 ,  C12Q1/6827 ,  C12Q1/6876 ,  C12Q1/6883 ,  C12Y101/01051 ,  C12Y101/01062 ,  G01N33/5067 ,  A61K48/00 ,  A61K48/0066 ,  C12N2310/14 ,  C12N2310/20 ,  C12N2310/531 ,  C12N2320/30 ,  C12N2320/34 ,  C12N2800/24 ,  C12N2800/80 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2333/4704 ,  G01N2800/085

摘要： Provided are compositions related to HSD17B13 variants, including nucleic acid molecules and polypeptides related to variants of HSD17B13, and cells comprising those nucleic acid molecules and polypeptides. Also provided are methods related to HSD17B13 variants. Such methods include methods for detecting the presence of the HSD17B13 rs72613567 variant in a biological sample comprising genomic DNA, for detecting the presence or levels of any one of variant HSD17B13 Transcripts C, D, E, F, G, and H, and particularly D, in a biological sample comprising mRNA or cDNA, or for detecting the presence or levels of any one of variant HSD17B13 protein Isoforms C, D, E, F, G, or H, and particularly D, in a biological sample comprising protein. Also provided are methods for determining a subject's susceptibility to developing a liver disease or of diagnosing a subject with liver disease.